MedPath

A prospective observational study to investigate the safety of SARS-Cov-2 vaccine for patients with advanced lung cancer who are treated with immune checkpoint inhibitor.

Not Applicable
Recruiting
Conditions
ung cancer
Registration Number
JPRN-UMIN000044213
Lead Sponsor
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Patients that doctor in charge consider them inappropriate as a subject Patients who had already infected with COVID-19

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath